Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 101–200 of 1,013
Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance
Wang, H., Gao, Z., Liu, X., Agarwal, P., Zhao, S., Conroy, D. W., Ji, G., Yu, J., Jaroniec, C. P., Liu, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02915-8 · Cited by 331
“M ultidrug resistance of cancer cells is a major reason for the failure of chemotherapy 1,2 . the cells left Chemotherapy can kill drug-sensitive cancer cells, but the drug-resistant behind can cause tumor recurrence (or relapse) and even cancer metastasis 3,4 .”
RetractedAcid-Active Cell-Penetrating Peptides for in Vivo Tumor-Targeted Drug Delivery
Jin, E., Zhang, B., Sun, X., Zhou, Z., Ma, X., Sun, Q., Tang, J., Shen, Y., Van Kirk, E., Murdoch, W. J., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja311180x · Cited by 329
Liang, Z., Wu, H., Xia, J., Li, Y., Zhang, Y., Huang, K., Wagar, N., Yoon, Y., Cho, H. T., Scala, S., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.017 · Cited by 330
“There are three well-known transporters [3]: ABCB1 (MDR-1/P-pg) [4], multidrug resistance-associated protein ABCC1 (MRP-1) [1], and ABCG2 (BCRP) [5].”
BackgroundZhang, W., Lu, J., Gao, X., Li, P., Zhang, W., Ma, Y., Wang, H., & Tang, B. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201710800 · Cited by 328
Recent advances in magnetic fluid hyperthermia for cancer therapy
Das, P., Colombo, M., & Prosperi, D. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2018.10.051 · Cited by 329
Understanding cancer and the anticancer activities of naphthoquinones – a review
Wellington, K. W. (2015) · RSC Advances · doi:10.1039/c4ra13547d · Cited by 316
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
“The development of simultaneous resistance to multiple drugs, of distinct chemical structures, different mechanisms of action and differing targets, is known as multidrug resistance (MDR) (Szakács et al., 2006).”
BackgroundCarrier-Free, Chemophotodynamic Dual Nanodrugs via Self-Assembly for Synergistic Antitumor Therapy
Zhang, R., Xing, R., Jiao, T., Ma, K., Chen, C., Ma, G., & Yan, X. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b02416 · Cited by 318
Patil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Resistance to chemotherapy: new treatments and novel insights into an old problem
Raguz, S., & Yagüe, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604510 · Cited by 312
“Most clinical trial end points have not been analysed yet; for an extended discussion of P-glycoprotein inhibitors in the clinic see Szakacs et al (2006).”
Magnetic field triggered drug release from polymersomes for cancer therapeutics
Oliveira, H., Pérez-Andrés, E., Thevenot, J., Sandre, O., Berra, E., & Lecommandoux, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.013 · Cited by 310
“A similar behaviour was previously described for other vesicular delivery systems [27, 28], where DOX encapsulation in the vesicular structures reduces the amount of available drug, what may potentially diminish unwanted off-target effects [29] and inhibit multi drug resistance [30].”
BackgroundTherapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules
Vigderman, L., & Zubarev, E. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.004 · Cited by 305
“This overcomes drug efflux from the cells which is responsible for drug-resistance [122],”
BackgroundMa, Y., Yang, Y., Wang, F., Moyer, M.-P., Wei, Q., Zhang, P., Yang, Z., Liu, W., Zhang, H., Chen, N., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308392 · Cited by 304
Cheng, W., Nie, J., Gao, N., Liu, G., Tao, W., Xiao, X., Jiang, L., Liu, Z., Zeng, X., & Mei, L. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201704135 · Cited by 304
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
Collateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
“ABC transorters play both excretory and protective physiological roles, eing endogenously expressed in the liver, kidneys, and intestines, nd preventing entry of xenobiotics at the blood–brain barrier, estis, and placenta (Gottesman et al., 2002; Szakacs et al., 2006; hou, 2008).”
BackgroundSelf-citationNanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines
Zhu, W., Shan, X., Wang, T., Shu, Y., & Liu, P. (2010) · International Journal of Cancer · doi:10.1002/ijc.25260 · Cited by 299
“; third, increased energy-dependent efflux of hydrophobic drugs, represented by overexpression of a family of energy-dependent transporters, known as ATP-binding cassette transporters, such as P-glycoprotein (Pgp), breast cancer resistance protein, etc.(5) MicroRNAs (miRNAs) are short noncoding RNA molecules, which po…”
BackgroundBattling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
“Importantly, dysregulation of thymidylate synthase [1], dihydrofolate reductase [2,3] and topoisomerases I and II [4,5] are known to cause resistance against 5-fluorouracil and tomudex [6], methotrexate [7] and doxorubicin [8], respectively.”
BackgroundJiang, L., Li, L., He, X., Yi, Q., He, B., Cao, J., Pan, W., & Gu, Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.004 · Cited by 294
Peetla, C., Vijayaraghavalu, S., & Labhasetwar, V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.004 · Cited by 289
“mechanisms of drug resistance, such as increased drug efflux via permeability glycoprotein (P-glycoprotein [P-gp]); also known as multidrug resistance [MDR] protein 1) extrusion pumps [4, 5], reduced drug influx, drug entrapment in intracellular vesicles [6, 7], activation of anti-apoptotic pathways, inactivation of a…”
BackgroundDoxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro
Kievit, F. M., Wang, F. Y., Fang, C., Mok, H., Wang, K., Silber, J. R., Ellenbogen, R. G., & Zhang, M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.024 · Cited by 289
“MDR generally reflects the overexpression of ATP-binding cassette (ABC) transporters which increase the efflux of a broad class of hydrophobic drugs from cancer cells [2].”
BackgroundStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Zhong, Y., Zhang, J., Cheng, R., Deng, C., Meng, F., Xie, F., & Zhong, Z. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.012 · Cited by 286
“The occurrence of drug-resistance is a major challenge for cancer chemotherapy [2,48].”
BackgroundNanayakkara, A. K., Follit, C. A., Chen, G., Williams, N. S., Vogel, P. D., & Wise, J. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19325-x · Cited by 282
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
“It has been used in the first-line treatment modalities of human malignancies, including testicular [1], ovarian [2, 3], cervical [4], bladder [5], head and neck [6], and small cell lung cancers (SCLCs) [3, 7, 8].”
Sharom, F. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00041 · Cited by 278
“Three different strategies for defeating Pgp have been described (1); “engage” (co-administration of anti-cancer drugs and modulators), “evade” (the use of anti-cancer drugs that are poor Pgp substrates), and “exploit” (specific targeting of the Pgp molecule).”
BackgroundMuller, M. P., Jiang, T., Sun, C., Lihan, M., Pant, S., Mahinthichaichan, P., Trifan, A., & Tajkhorshid, E. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00608 · Cited by 282
Selbo, P. K., Weyergang, A., Høgset, A., Norum, O.-J., Berstad, M. B., Vikdal, M., & Berg, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.06.008 · Cited by 282
Conjugated Polymer Nanoparticles for Imaging, Cell Activity Regulation, and Therapy
Wang, Y., Feng, L., & Wang, S. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201806818 · Cited by 279
Shrimali, D., Shanmugam, M. K., Kumar, A. P., Zhang, J., Tan, B. K. H., Ahn, K. S., & Sethi, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.023 · Cited by 277
“Multidrug resistance is also emerging as the major problem in the conventional treatment of cancer [3].”
BackgroundLoganzo, F., Tan, X., Sung, M., Jin, G., Myers, J. S., Melamud, E., Wang, F., Diesl, V., Follettie, M. T., Musto, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0862 · Cited by 278
“For example, ABCB1 (MDR1/P-glycoprotein) is associatedwith poor prognosis in hematopoietic cancers such as AML (5), and expression correlates with various features of some solid tumors (6, 7).”
BackgroundCancer cell nucleus-targeting nanocomposites for advanced tumor therapeutics
Pan, L., Liu, J., & Shi, J. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00081f · Cited by 276
Bao, L., Hazari, S., Mehra, S., Kaushal, D., Moroz, K., & Dash, S. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.024 · Cited by 275
Khdair, A., Chen, D., Patil, Y., Ma, L., Dou, Q. P., Shekhar, M. P. V., & Panyam, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.004 · Cited by 275
“In addition, overexpression of drug efflux transporters like Pglycoprotein (P-gp) [5] and sequestration of drug in acidic intracellular organelles [6] or in the acidic tumor microenvironment [7] reduce availability of the drug at its site of action inside the tumor cell.”
BackgroundHe, C., Liu, D., & Lin, W. (2015) · ACS Nano · doi:10.1021/nn506963h · Cited by 274
“chanisms of actions to achieve enhanced anticancer efficacy.(3) 5”
BackgroundGlutathione transferases and development of new principles to overcome drug resistance
Sau, A., Pellizzari Tregno, F., Valentino, F., Federici, G., & Caccuri, A. M. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.05.012 · Cited by 271
Han, S.-S., Li, Z.-Y., Zhu, J.-Y., Han, K., Zeng, Z.-Y., Hong, W., Li, W.-X., Jia, H.-Z., Liu, Y., Zhuo, R.-X., et al. (2015) · Small · doi:10.1002/smll.201402865 · Cited by 269
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 266
Das, V., Bhattacharya, S., Chikkaputtaiah, C., Hazra, S., & Pal, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28160 · Cited by 263
Wei, B., Pan, J., Yuan, R., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00209 · Cited by 265
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
“While tumor cells evade death through multiple mechanisms [3], overexpression of efflux transporters is an important source of drug resistance.”
BackgroundTaxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.011 · Cited by 261
Building a Multifunctional Aptamer-Based DNA Nanoassembly for Targeted Cancer Therapy
Wu, C., Han, D., Chen, T., Peng, L., Zhu, G., You, M., Qiu, L., Sefah, K., Zhang, X., & Tan, W. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4094617 · Cited by 260
Wu, C., Calcagno, A. M., & Ambudkar, S. V. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801020093 · Cited by 259
“However, how to tackle drug resistance using available pharmacological and structural information to select or design new inhibitors (reviewed in [3,49,50]) is now much clearer.”
BackgroundIs resistance useless? Multidrug resistance and collateral sensitivity
Hall, M. D., Handley, M. D., & Gottesman, M. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.003 · Cited by 259
Self-citationYu, G., Yu, S., Saha, M. L., Zhou, J., Cook, T. R., Yung, B. C., Chen, J., Mao, Z., Zhang, F., Zhou, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06574-7 · Cited by 255
Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Shukla, S., Wu, C.-P., & Ambudkar, S. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.205 · Cited by 253
“The active efflux of these chemotherapeutic drugs by ABCG2 can ultimately result in the development of MDR if overexpressed in cancer cells [4] .”
BackgroundInfluentialPan, L., Liu, J., He, Q., Wang, L., & Shi, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.040 · Cited by 252
“As a most widely studied adenosine triphosphate (ATP)-dependent active efflux pump, P-glycoprotein (P-gp) is often over-expressed in the plasma membrane of many MDR cells and plays a predominant role in transporting out chemotherapeutic agents such as daunorubicin, doxorubicin, paclitaxel, vinblastine, valinomycin etc…”
BackgroundDifferent strategies to overcome multidrug resistance in cancer
Saraswathy, M., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.06.004 · Cited by 248
“Table 1 shows the major ABC transporters associated with MDR and their substrate anticancer drugs (Gottesman et al., 2002; Szakács et al., 2006).”
BackgroundSynonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima
Tsai, C.-J., Sauna, Z. E., Kimchi-Sarfaty, C., Ambudkar, S. V., Gottesman, M. M., & Nussinov, R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.08.012 · Cited by 252
“The MDR1 gene product P-gp, an ATP-binding cassette (ABC) transporter, is an ATP-driven efflux pump for many substrate hydrophobic drugs that enter the cell via diffusion through the membrane.(2) Consequently, it is hypothesized to play a major role in multidrug resistance during chemotherapy in metastatic cancers.”
Self-citationYuan, Y., Zhang, J., Qi, X., Li, S., Liu, G., Siddhanta, S., Barman, I., Song, X., McMahon, M. T., & Bulte, J. W. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0503-4 · Cited by 247
Kim, K.-R., Kim, D.-R., Lee, T., Yhee, J. Y., Kim, B.-S., Kwon, I. C., & Ahn, D.-R. (2013) · Chemical Communications · doi:10.1039/c3cc38693g · Cited by 246
Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia
Liu, Y., Cheng, Z., Pang, Y., Cui, L., Qian, T., Quan, L., Zhao, H., Shi, J., Ke, X., & Fu, L. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0734-5 · Cited by 246
“ABC transporter and P-glycoprotein (P-gp), encoded by the MDR1 gene, play pivotal roles in this process [43, 44].”
BackgroundCell killing by antibody–drug conjugates
Kovtun, Y. V., & Goldmacher, V. S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.010 · Cited by 246
“Three ABC proteins, P-glycoprotein (also known as MDR1), multidrug resistance associated-protein 1 (MRP1, also known as ABCC1), and ABCG2 (also known as MXR or BCRP) were found to be expressed on certain cancer cells rendering them resistant to various hydrophobic drugs [50] including those used in ADCs.”
BackgroundErlinger, S., Arias, I. M., & Dhumeaux, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.047 · Cited by 244
Yu, M., Qi, B., Xiaoxiang, W., Xu, J., & Liu, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.001 · Cited by 234
“However, intrinsic or acquired drug resistance is still a major challenge [2].”
Resistance against novel anticancer metal compounds: Differences and similarities
Heffeter, P., Jungwirth, U., Jakupec, M., Hartinger, C., Galanski, M. S., Elbling, L., Micksche, M., Keppler, B., & Berger, W. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.02.002 · Cited by 242
Interstitial fluid flow in cancer: implications for disease progression and treatment
Munson, J., & Shieh, A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s65444 · Cited by 235
Mechanisms of Resistance to Antibody–Drug Conjugates
Loganzo, F., Sung, M., & Gerber, H.-P. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0408 · Cited by 231
“The drug transporter MDR1 is known to be induced in cancer cells during chronic exposure to other standard-of-care (unconjugated) tubulin inhibitors (41); hence, a role for resistance to the maytansine analog DM1 was conceivable, and is observed for T-DM1 in KPL-4-T-DM1-R cells.”
BackgroundBae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E.-S., Lee, K. C., & Youn, Y. S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.050 · Cited by 236
“Tumors display wide variances in cell differentiation and phenotype, and these variances may include low sensitivity or resistance to chemotherapeutics and pro-apoptotic agents [14].”
BackgroundThe controversial role of ABC transporters in clinical oncology
Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W., & Bates, S. E. (2011) · Essays in Biochemistry · doi:10.1042/bse0500209 · Cited by 235
Self-citationBeretta, G. L., Cassinelli, G., Pennati, M., Zuco, V., & Gatti, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.062 · Cited by 235
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy
Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Banerjee, S., Kong, D., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.06.001 · Cited by 233
The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis
Assaraf, Y. G. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.09.001 · Cited by 235
African Flora Has the Potential to Fight Multidrug Resistance of Cancer
Kuete, V., & Efferth, T. (2015) · BioMed Research International · doi:10.1155/2015/914813 · Cited by 227
“The overexpression of ABC transporters contributes to MDR and participates in the failure of cancer chemotherapy [7].”
BackgroundRecent advances in deep-sea natural products
Skropeta, D., & Wei, L. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70118b · Cited by 231
Role of microRNA in anticancer drug resistance
Zheng, T., Wang, J., Chen, X., & Liu, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24782 · Cited by 233
“ance of cancer cells to chemotherapy continues to be a major clinical obstacle to the successful treatment of cancer.(1) At present, the anticancer drug resistance is considered as a”
BackgroundPalanisamy, S., & Wang, Y.-M. (2019) · Dalton Transactions · doi:10.1039/c9dt00459a · Cited by 230
Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229
Xing, Y., Zhang, J., Chen, F., Liu, J., & Cai, K. (2017) · Nanoscale · doi:10.1039/c7nr01857f · Cited by 227
Cisplatin-Based Chemotherapy of Human Cancers.
Brown, A. M., Kumar, S., & Tchounwou, P. B. (2019) · PubMed · Cited by 318
Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer
Munoz, M., Henderson, M., Haber, M., & Norris, M. (2007) · IUBMB Life · doi:10.1080/15216540701736285 · Cited by 226
“MRP1 has since been closely linked to the development of clinical MDR in several types of cancer ( 1, 5 ) and an extraordinarily wide variety of transport substrates have been identified (Fig.”
BackgroundWang, Z., Wang, N., Liu, P., Chen, Q., Situ, H., Xie, T., Zhang, J., Peng, C., Lin, Y., & Chen, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2192 · Cited by 224
“com/oncotarget transporters is highly correlated with drug resistance [4].”
BackgroundZhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
“However, multidrug resistance (MDR), a phenomenon in which tumor cells display resistance to multiple structurally and functionally unrelated anticancer drugs, is a primary hindrance to curative cancer therapy [1–3].”
BackgroundGuo, X., Wei, X., Jing, Y., & Zhou, S. (2015) · Advanced Materials · doi:10.1002/adma.201502865 · Cited by 222
Role of Galectins in Tumors and in Clinical Immunotherapy
Chou, F.-C., Chen, H.-Y., Kuo, C.-C., & Sytwu, H.-K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020430 · Cited by 222
“Cancer cells develop several mechanisms to combat anticancer drugs, including decreased drug uptake, increased efflux via ATP-binding cassette (ABC) transporters, and increased drug metabolism and/or resistance to drug-induced apoptosis [57].”
BackgroundAkhavan, O., Ghaderi, E., & Emamy, H. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm34330d · Cited by 220
Mohammad, I. S., He, W., & Yin, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.038 · Cited by 218
O'Brien, F. E., Dinan, T. G., Griffin, B. T., & Cryan, J. F. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01557.x · Cited by 215
“However, clinical trials to date, which have focused exclusively on the use of P-gp inhibitors in combination with cytotoxic drugs in treatment resistant cancer, have not proven to be successful due to pharmacokinetic and pharmacodynamic limitations (Szakacs et al., 2006; Colabufo et al., 2010).”
BackgroundChen, Y., Tang, Y., Guo, C., Wang, J., Boral, D., & Nie, D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.030 · Cited by 219
“Of the 48 known human ABC transporters, 11 have already been shown to play roles in MDR in cancer cells [52].”
Amiri-Kordestani, L., Basseville, A., Kurdziel, K., Fojo, A. T., & Bates, S. E. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.002 · Cited by 219
“The first discovered human ABC transporter was P-glycoprotein (Pgp), encoded by the MDR1 gene; in all 48 ABC transporters have been identified in humans (Szakacs et al., 2006).”
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
Sung, M., Tan, X., Lu, B., Golas, J., Hosselet, C., Wang, F., Tylaska, L., King, L., Zhou, D., Dushin, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0403 · Cited by 215
Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy
Gao, M., Deng, J., Liu, F., Fan, A., Wang, Y., Wu, H., Ding, D., Kong, D., Wang, Z., Peer, D., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119486 · Cited by 218
“Efficient cancer treatment has been challenging because of the occurrence of multiple drug resistance (MDR) and the formation of metastasis [1].”
BackgroundSonic Hedgehog promotes multiple drug resistance by regulation of drug transport
Sims-Mourtada, J., Izzo, J. G., Ajani, J., & Chao, K. S. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210356 · Cited by 217
“Although ABC transporters are highly expressed in stem cells and during tissue regeneration, their regulation in the context of cancer is poorly understood (Szakacs et al., 2006).”
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Sajid, A., Rahman, H., & Ambudkar, S. V. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00612-3 · Cited by 201
Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy
Lee, S.-M., O’Halloran, T. V., & Nguyen, S. T. (2010) · Journal of the American Chemical Society · doi:10.1021/ja107333g · Cited by 213
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
Das, A., Durrant, D., Salloum, F. N., Xi, L., & Kukreja, R. C. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.10.003 · Cited by 212
“Unfortunately, most of the transport inhibitors have not translated in the clinic due to unfavorable side effects, toxic pharmacokinetic interactions or simply because the magnitude of improvement over conventional chemotherapeutic agents is either non-significant or inconclusive (Szakacs et al., 2006).”
BackgroundMechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents
Fojo, T., & Menefee, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm172 · Cited by 217
“generation of ABC transporter inhibitors have provided the basis for the initiation of clinical trials examining their ability to modulate drug sensitivity [20].”
BackgroundSmart Hydrogels – Synthetic Stimuli-Responsive Antitumor Drug Release Systems
Kasiński, A., Zielińska-Pisklak, M., Oledzka, E., & Sobczak, M. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s248987 · Cited by 208
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 209
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak, M., Wiktorowska-Owczarek, A., & Stanczak, A. (2021) · Molecules · doi:10.3390/molecules26092601 · Cited by 197
“They play significant roles in the protection of normal cells and tissues by regulating biological membrane permeability [79].”
BackgroundCurrent scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides
Mulder, K. C. L., Lima, L. A., Miranda, V. J., Dias, S. C., & Franco, O. L. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00321 · Cited by 207
“…target tissue, which can be particular to each patient; moreover, tumors can be positioned in places into which drug penetration is impaired or possibly sheltered by restricted environments due to amplified hydrostatic pressure in the tissue or modified tumor vasculatures (Szakacs et al., 2006).”
BackgroundRevisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
K. Tiwari, A., Sodani, K., Dai, C.-L., R. Ashby, C., & Chen, Z.-S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795164048 · Cited by 211
“As a result of their specificity for ABC transporters [5, 263] these compounds were effective not only in inhibiting ABCB1, but also ABCC1 and ABCG2.”
BackgroundInfluentialTrends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 208
“, MDR1 (multidrug resistance protein 1; also known as P-glycoprotein) expression—tumors have evolved a mechanism that allows them to take advantage of an unfavorable oxygen supply by reprogramming their metabolism and developing non-specific physico-chemical barrier mechanisms leading to an “ion trapping” phenomenon,…”
BackgroundBorst, P. (2012) · Open Biology · doi:10.1098/rsob.120066 · Cited by 212
“This pump can remove a large range of drugs from the cell, and upregulation of P-gp makes it possible for cancer cells to become completely resistant to some of the drugs intensively used in the clinic, notably taxanes, anthracyclines, epipodophylotoxins and Vinca alkaloids [13].”
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.